Secukinumab-bthr Medicine 03 June 2025 Extended indication Secukinumab-bthr monotherapy for treatment of moderate to severe Plaque psoriasis in adults and elderly who are candidates for systemic therapy. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Secukinumab-bthr Domain Chronic immune diseases Reason of inclusion Biosimilar BS Main indication Other chronic immune diseases Extended indication Secukinumab-bthr monotherapy for treatment of moderate to severe Plaque psoriasis in adults and elderly who are candidates for systemic therapy. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date 2025 Expected Registration February 2026 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks NCT05377944 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks